Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate

Innate Pharma (NASDAQ: IPHA) reported a first-half loss of $(0.24) per share, missing the analyst estimate of $(0.16) by 50%. This represents an improvement from a loss of $(0.28) per share in the same period last year. The company also reported sales of $6.583 million, falling short of the $9.100 million estimate by 27.66%, but showing a 19.47% increase from $5.510 million in the prior year.